arrow
V

Vip Viprakasit

Mahidol University
H指数:45
被引数:8,265

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Future-proofing thalassaemia care: harnessing scalable therapies, artificial intelligence, and global collaboration

为地中海贫血护理的未来做准备:利用可扩展疗法、人工智能和全球合作

2026-10-060
PRE
Human genetics implicates a BACH2–NRF2 axis in fetal haemoglobin activation

人类遗传学提示BACH2–NRF2轴在胎儿血红蛋白激活中的作用

Nature
IF48.5
2026-09-300
OAAI
Efficacy and safety of mitapivat in adults with transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE-T): a double-blind, randomised, multicentre, placebo-controlled, phase 3trial

米塔匹泛在依赖输血的α-地中海贫血或β-地中海贫血成人中的有效性和安全性(ENERGIZE-T):一项双盲、随机、多中心、安慰剂对照、III期临床试验

2026-09-121
PRE
Management of transfusion-dependent β-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources

新型疗法时代输血依赖性β-地中海贫血的管理:一种基于优先级的矩阵,适用于资源有限的环境

2025-12-310
PRE
Bridging Pharmacokinetics and Pharmacodynamics: A PBPK/PD Model-Based Approach for Deferasirox Dosing in Transfusion-Dependent Thalassemia

连接药代动力学与药效学:一种基于PBPK/PD模型的地拉罗司在输血依赖型地中海贫血中的给药方案

2025-09-180
OAAI
Efficacy and safety of luspatercept in non-transfusion-dependent β-thalassemia: long-term results from the BEYOND study

luspaterecpt 在非输血依赖性β-地中海贫血中的有效性和安全性:BEYOND研究的长期能力结果

2025-09-010
OAAI
Pharmacogenomic landscape of the Thai population from genome sequencing of 949 individuals
2024-12-280
OAAI
Bone mineral density in adult patients with pyruvate kinase deficiency on long-term mitapivat treatment

长期接受mitapivat治疗的丙酮酸激酶缺乏症成年患者的骨矿物质密度

2023-09-211
OAAI
The impact of in utero transfusions on perinatal outcomes in patients with alpha thalassemia major: the UCSF registry
2023-01-249
OAAI